anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The oral sulforaphane supplement is a myrosinase-active whole broccoli sprout material (EnduraCell Bioactive, Cell-Logic, Queensland, AU) containing 14 mg SFN per capsule. Three capsules will be consumed 90 min prior to the start of the acute exercise trial. The dose of 3 capsules is equivalent to approximately 220 µmol of SFN, which is comparable to that of other studies using broccoli sprout extracts and the recommended single dose.
Multiple myeloma (MM) is an incurable and recurrent malignancy characterized by abnormal plasma cell proliferation. There is an urgent need to develop effective drugs in MM. DCZ0825 is a small molecule compound derived from pterostilbene with direct anti-myeloma activity and indirect immune-killing effects though reversal of the immunosuppression. DCZ0825 inhibits the activity and proliferation of MM cells causing no significant toxicity to normal cells. Using flow cytometry, this study found that DCZ0825 induced caspase-dependent apoptosis in MM cells and arrested the cell cycle in the G2/M phase by down-regulating CyclinB1, CDK1 and CDC25. Moreover, DCZ0825 up-regulated IRF3 and IRF7 to increase IFN-γ, promoting M2 macrophages to transform into M1 macrophages, releasing the immunosuppression of CD4T cells and stimulated M1 macrophages and Th1 cells to secrete more INF-γ to form immune killing effect on MM cells. Treatment with DCZ0825 resulted in an increased proportion of positive regulatory cells such as CD4T, memory T cells, CD8T, and NK cells, with downregulation of the proportion of negative regulatory cells such as Treg cells and MDSCs. In conclusion, DCZ0825 is a novel compound with both antitumor and immunomodulatory activity.
If the study dose of 60 mg/m2/day at Dose Level 3 is well tolerated but does not show sufficient AC220 activity, the study may proceed to Dose Level 4 at 90 mg/m2/day. Patients will received etoposide and cytarabine on Days 1-5, and AC220 on Day 7 through 28. IT Methotrexate will be given to patients with ALL on Day 0, dose assigned by age. If toxicity at Dose Level 4 would allow further escalation, but demonstrated sufficient AC220 activity, no further dose escalation will be required.
An applicator device includes an applicator mitt. The applicator mitt includes a non-permeable layer configured to receive a user's hand when the non-permeable layer is in an open configuration. A fabric layer extends around the non-permeable layer and is impregnated with a liquid material. A packaging element surrounds the applicator mitt. The packaging element seals the non-permeable layer in a closed configuration. The packaging element is configured to be opened to provide the non-permeable layer in the open configuration. A method of applying a liquid material using the applicator device and a method of making the applicator device are also disclosed.
The intervention is a home-based, multimodal exercise prehabilitation program. Exercise was prescribed in one-hour sessions, performed a minimum of three times per week for three weeks, consisting of: 1) strength training, 2) aerobic exercise and 3) flexibility. The intervention group will receive weekly phone calls to gauge adherence, suggest modifications, provide support and track any adverse events.
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal malignancies that are characterized by ineffective hematopoiesis, progressive bone marrow failure, cytogenetic and molecular abnormalities, and increased risk for progression to acute myeloid leukemia (AML). It is a well-accepted theory that MDS and AML originate from primary alterations of hematopoietic stem cells (HSC) compartment, which confer a survival advantage to them at the expense of physiological hematopoiesis. More recently, there is growing evidences regarding the contribution of the bone marrow (BM) microenvironment to the pathogenesis of MDS and AML. Of particular interest, several studies have pointed towards a pivotal role of mesenchymal stromal cells (MSC), one of the main components of the BM niche, in the initiation and propagation of myeloid disorders. In this context, it is of clinical significance to better characterize the intrinsic defects harbored by MSC in MDS and AML context, as compared to physiological conditions. Such research initiative aims to dissect the cross-talk between malignant HSC and their BM partners in crime, further prospecting for innovative stromal-directed strategies for the treatment of MDS and AML.
Group 1 participants attend twice weekly progressive strength training classes with CPR certified and Strong People trained educators in fall 2019 for 12 weeks. Intervention Group.
Caring for patients with congenital upper limb differences (CULD) requires an understanding of unique psychosocial challenges. The study purpose was to describe the needs of children with CULD and their caregivers to develop a group curriculum. This mixed-method study included 13 mothers and one father of children with CULD (age 3 months to 14 years; mean 7.2 ± 4.3 years) using Patient-Reported Outcomes Measurement Information System Parent Proxy Reports and caregiver interviews. Patient-Reported Outcomes Measurement Information System Peer Relationships (M = 48.1 ± 10.9) and Pain Interference (M = 44.5 ± 7.5) T-scores were average with below average scores for Physical Function: Upper Extremity (M = 31.9 ± 12.1). Caregivers expressed high interest in groups to create community and mutual support covering themes of responding to questions from strangers, social and coping skills, building self-confidence, accessing resources, advocacy skills, and advice from adults with CULD. Access to a support group with a curriculum addressing CULD-related patient and family needs may improve care.
Trientine hydrochloride USP is 1,2-Ethanediamine,N,N'-bis(2-aminoethyl)-,dihydrochloride. It is a white to pale yellow crystalline powder. It is slightly soluble in methanol.   
The empirical formula is C 6H 20Cl 2N 4 with a molecular weight of 219.15. The structural formula is: 

  


  


Trientine hydrochloride is a chelating compound for removal of excess copper from the body. Trientine hydrochloride, USP is available as 250 mg capsules for oral administration. Trientine hydrochloride capsules, USP contain inactive ingredients stearic acid, the capsule shell contains D & C Red 28, FD & C Blue 1, gelatin, and titanium dioxide. The capsules are imprinted with black ink containing black iron oxide, potassium hydroxide, propylene glycol, shellac, strong ammonia solution.
Compounds for binding carbon monoxide are provided (e.g., to sequest carbon monoxide in a composition). Compounds according to certain embodiments include water soluble metal porphyrin complexes having substituents that provide for water solubility at physiological pH and form a hydrophobic carbon monoxide (CO)-binding pocket. In certain embodiments, metal porphyrin complexes exhibit limited cellular uptake. In some instances, the compounds described herein are capable of rescuing CO-poisoned red blood cells. Methods for treating a subject exposed to carbon monoxide (e.g., experiencing carbon monoxide poisoning) are also provided. Compositions for practicing the subject methods are also described.
A depilatory composition comprises an aqueous solution or emulsion (e.g. a paste or gel) of a depilatory agent, e,g. thioglycolic acid or a salt thereof, a film-forming polymer, which can be water-soluble, e.g. polyvinyl pyrrolidone, or insoluble, e.g. a rubber; and optionally an alkali, a hair swelling accelerating agent or a filler; it has a viscosity of 0.1 to 1,000 poises at 30 DEG C. …<??>The composition is spread on an area of skin having hair, the coating is allowed to dry naturally or by treating with hot air and/or by absorbing water into an absorbent sheet pressed onto the film; and the film is peeled off with the hairs embedded therein, optionally with use of a presure-sensitive adhesive sheet placed on the film. …<??>There is no unpleasant odor due to liberation of hair decomposition vaporous products; and the method is not painful.
A therapeutic composition and a method for the treatment of cancer by depletion of arginine without systemic complications comprising an arginine decomposing enzyme and protein breakdown inhibitors, a nitric oxide donor, a pressor peptide, and prostacyclin. The composition may further include an amino acid mixture lacking arginine, an antidote for cyanide, blood plasma or its derivatives, and/or a preparation of arginine. The arginine decomposing enzyme may modified to increase circulation half-life and can be type I liver arginase, or type II of human or animal, partially purified, or recombinant, or even bacterial origin. It may be administered as a drug or released from the patient's own tissue. Endogenous production of arginine, particularly via so-called intestinal-kidney axis, can be beneficially inhibited at several enzymatic steps, allowing for deeper reductions of circulating arginine. Different components of the composition may be administered separately, or in suitable mixtures, allowing for needed adjustments during the treatment.
Risk Summary

Based on human data from published literature, cisplatin injection can cause fetal harm when administered to pregnant women. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Data demonstrates transplacental transfer of cisplatin. Exposure of pregnant women to cisplatin-containing chemotherapy has been associated with oligohydramnios, intrauterine growth restriction, and preterm birth. Cases of neonatal acute respiratory distress syndrome, cytopenias, and hearing loss have been reported. Cisplatin injection administration to animals during and after organogenesis resulted in teratogenicity. A published study in mice showed placental transfer of cisplatin increased with placenta maturation.

The background risk of major birth defects and miscarriage for the indicated populations are unknown. However, the background risk in the U.S. general population of major birth defects is 2-4% and of miscarriage is 15-20% of clinically recognized pregnancies.
The invention provides a foamable composition for tooth bleaching which can be a one- or two-component system. The system has at least one peroxide compound, and at least one foaming agent. The composition can also contain at least one source of calcium, strontium and mixtures thereof, at least one de-sensitizing agent and at least one source of phosphate. The composition can produce a longer-lasting, collapsible foam structure with enhanced whitening action. The foamable composition can also be a one-component multi-phase system. A two-component composition can be packed in a two-compartment syringe. The syringe can also be fitted with a dispensing tip which may or may not have a static mixer.
Patients receive pramipexole and placebo. The dosage of pramipexole is 0.125 milligrams (mg) three times per day in the first week, 0.250 mg three times per day in the second week, 0.5 mg three times per day in the third week, and 0.75 mg three times per day in the fourth week and thereafter.
Parents of the primary school children to be recruited for the study. Focus group discussion in a group of 3 of ten in each group.
Participants will attend a baseline and end of the study visit (12-month time point) to the Women's Cancer Survivorship Clinic to undertake the baseline and complete end of study assessments. They will complete ePRO at baseline and at 12 months. They will have usual follow up care over the 12 month period of the study. Where participants in the control arm contact the Survivorship team for clinical or other advice, they will be referred to the usual care pathway.
The dosing schedule will be be based on a 28-day cycle. The starting dose schedule is PLD on Day 1 plus VTX-2337 on Day 3, Day 10, and Day 17 for the first 4 cycles. Starting with cycle 5, the dose regimen will be PLD on Day 1 plus VTX-2337 on Day 3 only, without additional doses of VTX-2337 on Days 10 and Day 17.
The volunteers will follow the assigned treatment for 6 weeks (PROBIOTICS_AB-DENTALAC CHEWING GUM. Orally) , which will consist of the consumption of 2 chewing gums a day. The chewing gum should be chewed for at least 15-20 minutes at least 1 hour after the consumption of food. For at least 1 hour after the consumption of chewing gum, volunteers will not be able to consume food, drink (except water) or clean their teeth. Adherence to the treatment will be made by returning the empty containers after 6 weeks.
Calcium (Ca2+) is a versatile intracellular second messenger that regulates several signaling pathways involved in growth, development, stress tolerance, and immune response in plants. Autoinhibited Ca2+-ATPases (ACAs) play an important role in the regulation of cellular Ca2+ homeostasis. Here, we systematically analyzed the putative OsACA family members in rice, and according to the phylogenetic tree of OsACAs, OsACA9 was clustered into a separated branch in which its homologous gene in Arabidopsis thaliana was reported to be involved in defense response. When the OsACA9 gene was knocked out by CRISPR/Cas9, significant accumulation of reactive oxygen species (ROS) was detected in the mutant lines. Meanwhile, the OsACA9 knock out lines showed enhanced disease resistance to both rice bacterial blight (BB) and bacterial leaf streak (BLS). In addition, compared to the wild-type (WT), the mutant lines displayed an early leaf senescence phenotype, and the agronomy traits of their plant height, panicle length, and grain yield were significantly decreased. Transcriptome analysis by RNA-Seq showed that the differentially expressed genes (DEGs) between WT and the Osaca9 mutant were mainly enriched in basal immune pathways and antibacterial metabolite synthesis pathways. Among them, multiple genes related to rice disease resistance, receptor-like cytoplasmic kinases (RLCKs) and cell wall-associated kinases (WAKs) genes were upregulated. Our results suggest that the Ca2+-ATPase OsACA9 may trigger oxidative burst in response to various pathogens and synergically regulate disease resistance and leaf senescence in rice.
<P>PROBLEM TO BE SOLVED: To provide extract of the petals or the like of Rosa rugosa Thunb. as a highly safe natural product for human body, useful against hyperglycemia, diabetes and obesity attributable to meals or the like, and to provide a method for using the extract.  <P>SOLUTION: An α-amylase inhibitor, an α-glucosidase inhibitor and a glucose enteric absorption inhibitor are provided, each being characterized by comprising, as active ingredient, extract of the petals or fruits of Rosa rugosa Thunb. The extract is obtained using water, an organic solvent or hydrous organic solvent as extractant. Uses of these inhibitors are also provided.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Students in control groups were applied the student information form and the pretest of the CRCF between May 18 and 20, 2021 before the education. The students in the control group continued their current standard education process. After the education sessions were completed, control groups were applied the CRCF as a posttest on June 28, 2021.
No adverse effects were noted in rats and monkeys after 26 once-weekly subcutaneous romosozumab-aqqg doses up to 100 mg/kg, equivalent to systemic exposures of 37 and 90 times, respectively, the systemic exposure observed in humans following a monthly subcutaneous dose of 210 mg EVENITY (based on AUC comparison).

Bone safety studies of up to 12-month duration were conducted in ovariectomized rats and monkeys with once-weekly romosozumab-aqqg doses yielding exposures ranging from 1 to 21 times the systemic exposure in humans given monthly doses of 210 mg, based on AUC comparison. Romosozumab-aqqg increased bone mass and improved cancellous bone microarchitecture and cortical bone geometry by increasing bone formation on periosteal, endocortical, and trabecular surfaces, and decreasing bone resorption on trabecular and endocortical surfaces. The increases in bone mass were significantly correlated with increases in bone strength. In rats and monkeys, bone quality was maintained at all skeletal sites at doses ranging from 1 to 21 times human exposure, and slightly improved in vertebrae at 19 to 21 times human exposure. There was no evidence of mineralization defects, osteoid accumulation, or woven bone formation.
Volunteers who wish to participate in the study will be interviewed by phone to verify that they meet the main inclusion criteria. Volunteers who meet the main inclusion criteria will be invited to an information and screening visit to resolve any doubts. Volunteers who agree to participate in the study will sign the informed consent and will be randomly allocated to one of the two arms of the study and will be provided with any required material.

During the intervention, volunteers will attend 4 Clinical investigation visits. The first one will be carried out on the first day of the study and the last one will take place at the end of the 12 weeks. In both visits anthropometric and body composition measurements, blood pressure, stool and blood samples, as well as data about dietary, physical activity and gastrointestinal symptoms will be taken. In the second and the third visits anthropometric, body composition, blood pressure and a blood sample will be taken. In the first and the third visits glucose monitoring sensor will be put and in the second and the fourth visits this glucosae monitoring sensor will be retired.
The present invention pertains to a Chinese traditional patent medicine - a bagged tea, oral liquor or a medicine pill for treating hypertension, which is based on the secret prescription and combined with the modern pharmaceutical technology to prepare the present invention thereof. Five traditional Chinese medicines of hawthorn fruit, barbary wolfberry fruit, twotooth achyranthes root, lalang grass rhizome and eucommia bark are carried out the impurity removal, cleaning and drying, the medicines are further mixed evenly according to the weight proportion of 25: 25: 25: 20: 5 and broken into the rice-shaped granules, the mesh disinfected paper bag which does not tend to melt is used for packaging, and each bagged tea is prepared into a weight of 20g. The present invention can be prepared into the oral liquor or medicine pill by modern pharmaceutical technology according to the prescription and the proportion. The medicine has the effects of removing liver fire, purging fire, clearing heart fire, cooling blood, tonifying kidney, benefiting yin, relieving rigidity of muscles, activating blood circulation, and nourishing liver and kidney. When in use, the bagged tea, oral liquor or medicine pill can be chosen respectively for the treatment according to the living habits and environmental characteristics of the patients. The present invention has the advantages of convenience, fast response, radical cure, low price and so on, furthermore, the taste is sweet and sour and thus being easy to be popularized.
Zonisamide (Zonegran®) 300 mg. Hard white capsule. The total length of zonisamide treatment will be 20 and 24 weeks ± 2 weeks including one or two 4 week titration phases in the placebo and zonisamide groups respectively. Dosing will be down titrated after finished study during 2-3 weeks.The maximum dose after titration will be administrated once daily. Evening medication should be taken 2 hours before bedtime. The tablets will be swallowed with 200 ml of water (room temperature) in an upright body position.
PROBLEM TO BE SOLVED: To obtain the above composition, containing a hydrolysate of yeast and a diuretic and useful for prevention, improvement and treatment of morbid skin irritation due to atopic dermatitis and irregular living rhythm. SOLUTION: This composition includes (A) a hydrolysate of yeast and (B) a diuretic at a weight rate of 3:7-7:3. As the component A, a product obtained by hydrolyzing bear yeast (saccharomyces cerevisiae) with a protease is preferable. It is preferable to use pepsin as a protease. In order to hydrolyze the yeast with protease, water 2-20 time amount of the yeast water and protease 1/100-1/10 time of the yeast are added to the yeast and the mixture is favorably allowed to react for several days at 35-40 deg.C. As the component B, a product after removal of the solvent from an aqueous extract of Polyporaceae ganoderma lucidum is combined together with a product after removal of the solvent from an aqueous extract of Kochiae fructus which consists of a dried fruit of Chenopodiaceae kochia scoparia schrad. It is favorable to use Ganoderma lucidum and Kochia scoparia schrad at a ratio of 1:3-3:1.
Studies in adult healthy subjects showed that levocetirizine at doses of 2.5 mg and 5 mg inhibited the skin wheal and flare caused by the intradermal injection of histamine. In contrast, dextrocetirizine exhibited no clear change in the inhibition of the wheal and flare reaction. Levocetirizine at a dose of 5 mg inhibited the wheal and flare caused by intradermal injection of histamine in 14 pediatric subjects (aged 6 to 11 years) and the activity persisted for at least 24 hours. The clinical relevance of histamine wheal skin testing is unknown.

A QT/QTc study using a single dose of 30 mg of levocetirizine did not demonstrate an effect on the QTc interval. While a single dose of levocetirizine had no effect, the effects of levocetirizine may not be at steady state following single dose. The effect of levocetirizine on the QTc interval following multiple dose administration is unknown. Levocetirizine is not expected to have QT/QTc effects because of the results of QTc studies with cetirizine and the long postmarketing history of cetirizine without reports of QT prolongation.
Study Design will be randomized clinical trial. Study setting will be Sehat medical complex Lahore. Study Duration will be 4 months after synopsis approval Sample size will be 40 calculated by Epitool ,intervention group will be Group A: Radial Shock Therapy(RST) , Group B: Graston Instrument Assisted Soft Tissue Mobilization (GIASTM). Purposive sampling technique will be implanted. Both genders (male/female).Age 20 to 45 years, Pre-diagnosed with chronic plantar fasciitis, Heel pain will be included. Patients with rheumatoid arthritis, osteoporosis and ankle and foot bursitis were excluded. VAS scale (visual analogue scale), Foot function index (FFI), 12-Item Short-Form Health Survey and goniometer will be data collection tools. SPSS version 25 will be used for statistical analysis. Shapiro-wilks test for normality will be used to assess the normality of the data after which it will be decided either parametric or non-parametric test will be used within and across the group.
All subjects will receive 1.47umol/kg/day sulforaphane for 12 weeks. Pills are taken once a say with a meal.
Collect tracheal and pulmonary secretions. All patients (n: 72) will be submitted to endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage.
Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.